Strategies to reduce hemostatic activation during cardiopulmonary bypass

Thrombosis Research

Volumn 117, Issue 6, 2006, Pages 689-703

  Eisses, Michael J ^a   Velan, Tomas ^b   Aldea, Gabriel S ^b   Chandler, Wayne L ^b  

^a Landstuhl Regional Medical Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cardiopulmonary bypass; Computer modeling; Hemostatic regulation

Indexed keywords

AMINOCAPROIC ACID; D DIMER; FIBRIN; HEPARIN; PLASMIN; THROMBIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER MODEL; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; IN VIVO STUDY; MALE; MEASUREMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

6-AMINOCAPROIC ACID; AGED; ANTIFIBRINOLYTIC AGENTS; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; COHORT STUDIES; COMPUTER SIMULATION; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMOSTASIS; HEPARIN; HUMANS; KINETICS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PLASMIN; THROMBIN;

EID: 33646028770     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.05.028     Document Type: Article

References (65)

1. Aldea G.S., Soltow L.O., Chandler W.L., Triggs C.M., Vocelka C.R., Crockett G.I., et al. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg 123 (2002) 742-755
2. Despotis G.J., Avidan M.S., and Hogue C.W.J. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 72 (2001) S1821-S1831
3. Aldea G.S., O'Gara P., Shapira O.M., Treanor P., Osman A., Patalis E., et al. Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits. Ann Thorac Surg 65 (1998) 425-433
4. Aldea G.S., Zhang X., Memmolo C.A., Shapira O.M., Treanor P., Kupferschmid J.P., et al. Enhanced blood conservation in primary coronary artery bypass surgery using heparin-bonded circuits with lower anticoagulation. J Card Surg 11 (1996) 85-92
5. Aldea G.S., Doursounian B.A., O'Gara P., Treanor P., Shapira O.M., Lazar H.L., et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective randomized study. Ann Thorac Surg 62 (1996) 410-418
6. Shapira O.M., Aldea G.S., Zelingher J., Volpe C., Fitzgerald C., DeAndrade K., et al. Enhanced blood conservation and improved clinical outcome after valve surgery using heparin-bonded cardiopulmonary bypass circuits. J Card Surg 11 (1996) 307-317
7. Mann K.G., Butenas S., and Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 23 (2003) 17-25
8. Diamond S.L. Engineering design of optimal strategies for blood clot dissolution. Annu Rev Biomed Eng 1 (1999) 427-461
9. Chandler W.L., Alessi M.C., Aillaud M.F., Henderson P., Vague P., and Juhan-Vague I. Clearance of TPA and TPA/PAI-1 complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 96 (1997) 761-768
10. Chandler W.L., Levy W.C., and Stratton J.R. The circulatory regulation of TPA and UPA secretion, clearance and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Circulation 92 (1995) 2984-2994
11. Crookston K.P., Marsh C.L., and Chandler W.L. A kinetic model of the circulatory regulation of tissue plasminogen activator during orthotopic liver transplantation. Blood Coagul Fibrinolysis 11 (2000) 79-88
12. Chandler W.L., and Velan T. Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass. Blood 101 (2003) 4355-4362
13. Velan T., and Chandler W.L. Effects of surgical trauma and cardiopulmonary bypass on active thrombin concentrations and the rate of thrombin inhibition in vivo. Pathophysiol Haemost Thromb 33 (2004) 144-156
14. Chandler W.L. A kinetic model of the circulatory regulation of tissue plasminogen activator. Thromb Haemost 66 (1991) 321-322
15. Chandler W.L., Levy W.C., Veith R.C., and Stratton J.R. A kinetic model of the circulatory regulation of tissue plasminogen activator during exercise, epinephrine infusion, and endurance training. Blood 81 (1993) 3293-3302
16. Chandler W.L., and Velan T. Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass. Thromb Res 112 (2004) 185-192
17. Chandler W.L., Alessi M.C., Aillaud M.F., Vague P., and Juhan-Vague I. Formation, inhibition and clearance of plasmin in vivo. Haemostasis 30 (2000) 204-218
18. Chandler W.L., and Velan T. Plasmin generation and D-dimer formation during cardiopulmonary bypass. Blood Coagul Fibrinolysis 15 (2004) 583-591
19. Eisses M.J., Seidel K., Aldea G.S., and Chandler W.L. Reducing hemostatic activation during cardiopulmonary bypass: a combined approach. Anesth Analg 98 (2004) 1208-1216
20. Rånby M., Sundell B., and Nilsson T.K. Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 62 (1989) 917-922
21. Keber D. Mechanism of tissue plasminogen release during venous occlusion. Fibrinolysis 2 Suppl 2 (1988) 96-103
22. Keber D., Stegnar M., and Kluft C. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion. Thromb Haemost 63 (1990) 72-75
23. Keber D., Blinc A., and Fettich J. Increase of tissue plasminogen activator in limbs during venous occlusion: a simple haemodynamic model. Thromb Haemost 64 (1990) 433-437
24. Valen G., Eriksson E., Risberg B., and Vaage J. Fibrinolysis during cardiac surgery. Release of tissue plasminogen activator in arterial and coronary sinus blood. Eur J Cardiothorac Surg 8 (1994) 324-330
25. Chandler W.L., Fitch J.C.K., Wall M.H., Verrier E.D., Cochran R.P., Soltow L.O., et al. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemost 74 (1995) 1293-1297
26. Spannagl M., Dooijewaard G., Dietrich W., and Kluft C. Protection of single-chain urokinase-type plasminogen activator (scu-PA) in aprotinin treated cardiac surgical patients undergoing cardiopulmonary bypass. Thromb Haemost 73 (1995) 825-828
27. Thorsen S. The mechanism of plasminogen activation and the variability of the fibrin effector during tissue-type plasminogen activator-mediated fibrinolysis. Ann N Y Acad Sci 667 (1992) 52-63
28. Weisel J.W., Veklich Y., Collet J.P., and Francis C.W. Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost 82 (1999) 277-282
29. Anonick P.K., and Gonias S.L. Soluble fibrin preparations inhibit the reaction of plasmin with alpha 2-macroglobulin. Comparison with alpha 2-antiplasmin and leupeptin. Biochem J 275 (1991) 53-59
30. 2-antiplasmin and plasmin, stopped-flow fluorescence kinetics. FEBS Lett 387 (1996) 58-62
31. Amiral J., Minard F., Plassart V., Vissac A.M., and Chambrette B. Reactivity of D-dimer assays with the fibrinogen-fibrin split products generated by thrombolytic agents. Blood Coagul Fibrinolysis 1 (1990) 525-530
32. Franks J.J., Kirsch R.E., Kao B., and Kloppel T.M. Fibrinogen and fibrinogen-related peptides in cancer. In: Mariani G. (Ed). Pathophysiology of plasma protein metabolism (1984), Plenum Press, New York 265-278
33. Kornberg A., Francis C.W., and Marder V.J. Plasma crosslinked fibrin polymers: quantitation based on tissue plasminogen activator conversion to D-dimer and measurement of normals and patients with acute thrombotic disorders. Blood 80 (1992) 709-717
34. Liang K.Y., and Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 73 (1986) 13-22
35. Zeger S.L., Liang K.Y., and Albert P.S. Models for longitudinal data: a generalized estimating equation approach. Biometrics 44 (1988) 1049-1060
36. Royall R.M. Model robust confidence intervals using maximum likelihood estimators. Int Stat Rev 54 (1986) 221-226
37. Brommer E.J.P., Derkx F.H.M., Schalekamp M.A.D.H., Dooijewaard G., and Klaauw M.M.vd. Renal and hepatic handling of endogenous tissue-type plasminogen activator and its inhibitor in man. Thromb Haemost 59 (1988) 404-411
38. Jørgensen M., Petersen K.R., Vinberg N., Jespersen J., Gram J., and Tønnesen K.H. Mean transit times and the sites of synthesis and catabolism of tissue plasminogen activator and plasminogen activator inhibitor type 1 in young subjects. Blood Coagul Fibrinolysis 12 (2001) 643-650
39. Jørgensen M., Tønnesen K.H., Petersen K.R., Jespersen J., Gram J., and Vinberg N. Splanchnic extraction and clearance of tissue plasminogen activator (t-PA) after injection of recombinant t-PA (Actilyse®) in resting healthy subjects is proportional to the arterial concentration. Blood Coagul Fibrinolysis 13 (2002) 331-338
40. Nossel H.L., Yudelman I., Canfield R.E., Butler V.P., Spanondis K., Wilner G.D., et al. Measurement of fibrinopeptide A in human blood. J Clin Invest 54 (1974) 43-53
41. Nishida H., Aomi S., Tomizawa Y., Endo M., Koyanagi H., Nojiri C., et al. Comparative study of biocompatibility between the open circuit and closed circuit in cardiopulmonary bypass. Artif Organs 23 (1999) 547-551
42. Keuren J.F., Wielders S.J., Willems G.M., Morra M., and Lindhout T. Fibrinogen adsorption, platelet adhesion and thrombin generation at heparinized surfaces exposed to flowing blood. Thromb Haemost 87 (2002) 742-747
43. Niimi Y., Ichinose F., Ishiguro Y., Terui K., Uezono S., Morita S., et al. The effects of heparin coating of oxygenator fibers on platelet adhesion and protein adsorption. Anesth Analg 89 (1999) 573-579
44. Nakajima T., Osawa S., Ogawa M., Sasaki T., Izumoto H., Yagi Y., et al. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment. Asaio J 42 (1996) 301-305
45. Gorman R.C., Ziats N.P., Rao A.K., Gikakis N., Sun L., Khan M.M.H., et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 111 (1996) 1-12
46. Spiess B.D., Vocelka C., Cochran R.P., Soltow L., and Chandler W.L. Heparin coated bypass circuits, Carmeda®, suppresses the release of tissue plasminogen activator during coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 12 (1998) 299-304
47. Singer A.J., and Clark R.A.F. Cutaneous wound healing. N Engl J Med 341 (1999) 738-746
48. 78]plasminogen activation by native tissue-type plasminogen activator and variants that lack either the finger of kringle-2 domain. J Biol Chem 272 (1996) 2183-2191
49. Anand S., Wu J.H., and Diamond S.L. Enzyme-mediated proteolysis of fibrous biopolymers: dissolution front movement in fibrin or collagen under conditions of diffusive or convective transport. Biotech Bioeng 48 (1995) 89-107
50. Wu J.H., and Diamond S.L. A fluorescence quench and dequench assay of fibrinogen polymerization, fibrinogenolysis and fibrinolysis. Anal Biochem 224 (1995) 83-91
51. Zamarron C., Lijnen H.R., and Collen D. Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator. J Biol Chem 259 (1984) 2080-2083
52. Suenson E., Bjerrum P., Holm A., Lind B., Meldal M., Selmer J., et al. The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation. J Biol Chem 265 (1990) 22228-22237
53. Lukasiewicz H., and Niewiarowski S. In vitro studies on the mechanism of the antifibrinolytic action of E-aminocaproic acid (EACA). Thromb Diath Haemorrh 19 (1968) 584-592
54. Urano T., de Serrano V.S., Gaffney P.J., and Castellino F.J. Effectors of the activation of human [Glu1]plasminogen by human tissue plasminogen activator. Biochemistry 27 (1988) 6522-6528
55. Despotis G.J., Joist J.H., Hogue C.W.J., Alsoufiev A., Joiner-Maier D., Santoro S.A., et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 76 (1996) 902-908
56. Tayama E., Hayashida N., Akasu K., Tomokazu K., Fukunaga S., Akashi H., et al. Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded Bioline system. Artif Organs 24 (2000) 618-623
57. te Velthuis H., Baufreton C., Jansen P.G., Thijs C.M., Hack C.E., Sturk A., et al. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations. J Thorac Cardiovasc Surg 114 (1997) 117-122
58. De Somer F., Van Belleghem Y., Caes F., Francois K., Van Overbeke H., Arnout J., et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg 123 (2002) 951-958
59. de Haan J., Schonberger J., Haan J., van Oeveren W., and Eijgelaar A. Tissue-type plasminogen activator and fibrin monomers synergistically cause platelet dysfunction during retransfusion of shed blood after cardiopulmonary bypass. J Thoracic Cardiovasc Surg 106 (1993) 1017-1023
60. Slaughter T.F., Faghih F., Greenberg C.S., Leslie J.B., and Sladen R.N. The effects of e-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. Anesth Analg 85 (1997) 1221-1226
61. Higgins D., Lewis S., and Shafer J. Steady state kinetic parameters for the thrombin catalyzed conversion of human fibrinogen to fibrin. J Biol Chem 258 (1983) 9276-9282
62. Picozzi M., and De Cristofaro R. Effect of temperature on the association step in thrombin-fibrinogen interaction. Biochem J 294 (1993) 563-567
63. Lucas M.A., Fretto L.J., and McKee P.A. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 258 (1983) 4249-4256
64. Hekman C.M., and Loskutoff D.J. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Arch Biochem Biophys 262 (1988) 199-210
65. Coleman P.L., Patel P.D., Cwikel B.J., Rafferty U.M., Sznycer R., and Gelehrter T.C. Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem 261 (1986) 4352-4357